Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

  • Min Wu Chao (Contributor)
  • Li Hsun Chang (Contributor)
  • Huang Ju Tu (Contributor)
  • Chao-Di Chang (Contributor)
  • Mei-Jung Lai (Contributor)
  • Yi Ying Chen (Contributor)
  • Jing-Ping Liou (Contributor)
  • Che Ming Teng (Contributor)
  • Shiow-Lin Pan (Contributor)



Table S1. IC50 of MPT0E028 and SAHA in pancreatic cell lines. AsPC-1, PANC-1, and BxPC-3 cells were treated with different concentrations of MPT0E028 or SAHA for 72â h. IC50 (the half maximal inhibitory concentration) was determined by MTT assay. (DOCX 12 kb)
Date made availableMay 29 2019
PublisherUnknown Publisher

Cite this